Added to YB: 2026-09-18
Pitch date: 2026-09-15
ACTU [neutral]
Actuate Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
Market Cap
$23.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-1.11
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 3 - Actuate Therapeutics, Inc.
ACTU (quick overview): Actuate’s randomized Phase 2 pancreatic-cancer trial showed median overall survival of 10.1 months with IV elraglusib plus chemotherapy versus 7.2 months for chemotherapy alone, with a 0.62 hazard ratio. A 76 M&A score reflects potential interest in a differentiated combination backbone, but the thesis depends on oral elraglusib reproducing or improving the exposure-response relationship; RAS-combination evidence remains preclinical, a Phase 3 trial is required, and $4.4 million of Q2 cash plus a going-concern disclosure creates severe capital pressure.
Read full article (2 min)